Home > Insider Trading > Filing (0001246360-15-002048)

Filing Details

Accession Number:: 0001246360-15-002048
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-05-08 17:07:09
Reporting Period:: 2015-05-06

Filing Date:: 2015-05-08
Accepted Time:: 2015-05-08 17:07:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559209	Glen Williams	33 Hayden Ave Lexington MA 02421	Svp, Technical Operations	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-05-06	833	$40.32	1,301	No	4	M	Direct
Common Stock	Acquisiton	2015-05-06	833	$57.56	2,134	No	4	M	Direct
Common Stock	Disposition	2015-05-06	666	$203.99	1,468	No	4	S	Direct
Common Stock	Disposition	2015-05-06	400	$204.94	1,068	No	4	S	Direct
Common Stock	Disposition	2015-05-06	400	$206.27	668	No	4	S	Direct
Common Stock	Disposition	2015-05-06	100	$206.97	568	No	4	S	Direct
Common Stock	Disposition	2015-05-06	100	$215.26	468	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-05-06	833	$0.00	833	$40.32
Common Stock	Stock Option (Right to Buy)	Disposition	2015-05-06	833	$0.00	833	$57.56

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,835		2023-06-06	No	4	M	Direct
14,167		2022-10-04	No	4	M	Direct

Footnotes

The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2015.
25% of the total number of shares subject to the option vest and become exercisable on 06/06/2014 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
25% of the total number of shares subject to the option vest and become exercisable on 09/24/2013 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $203.37 to $204.30. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $204.60 to $205.18. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $205.87 to $206.83. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed through a broker-dealer at a price of $206.97.
This transaction was executed through a broker-dealer at a price of $215.26.